Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Account Payables (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Change in Account Payables for 12 consecutive years, with -$30000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Account Payables fell 700.0% year-over-year to -$30000.0, compared with a TTM value of -$30000.0 through Sep 2025, down 76.47%, and an annual FY2024 reading of -$29000.0, down 390.0% over the prior year.
  • Change in Account Payables was -$30000.0 for Q2 2025 at Arcadia Biosciences, up from -$51000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $18000.0 in Q3 2021 and bottomed at -$54000.0 in Q1 2021.
  • Average Change in Account Payables over 5 years is -$5062.5, with a median of $6000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 1100.0% in 2023, while the deepest fall reached 760.0% in 2023.
  • Year by year, Change in Account Payables stood at $13000.0 in 2021, then crashed by 92.31% to $1000.0 in 2022, then surged by 1100.0% to $12000.0 in 2023, then plummeted by 525.0% to -$51000.0 in 2024, then surged by 41.18% to -$30000.0 in 2025.
  • Business Quant data shows Change in Account Payables for RKDA at -$30000.0 in Q2 2025, -$51000.0 in Q3 2024, and $5000.0 in Q2 2024.